Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
Earnings Data
Report Date
May 18, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.19Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights major strategic and operational progress: submission of GraftAssureDx to the FDA, robust early clinical engagement (registry and head-to-head data), successful $26M financing with strategic investor support, a clear U.S. reimbursement pathway (Medicare rate and MolDx Z-code submission), and a defined plan to expand into heart transplants via a 510(k) pathway. Near-term risks include low expected lab revenue in Q1, front-loaded cash burn and higher quarterly spending, an intangible write-down on oncology assets, and reimbursement/operational complexity in EU/UK and MAC territories. Overall, the positives—regulatory milestone, strong external validation, funding, and an explicit commercialization plan—outweigh the near-term financial and market-access risks, supporting an optimistic outlook while acknowledging execution risk.Company Guidance
FDA Submission — GraftAssureDx
Submitted GraftAssureDx to the FDA for review; company believes it is the first dd-cfDNA assay submitted for FDA authorization. This is a major regulatory milestone and shifts the company's focus toward product launch and commercialization.
Strong Early Clinical Engagement and Registry Progress
GALACTIC registry momentum: 28 centers have started the process to become trial sites (≈56% of the 50-center goal) and management reports 37 transplant centers engaged in the U.S. Registry target: 5,000 patients across ~50 centers (~100 patients per center) with each patient tested ~10x.
Positive Head-to-Head Data and Early Adoption
A top transplant center presented head-to-head data on >140 patient samples showing equivalent results to a national reference lab using GraftAssure; that center intends to bring GraftAssure into its core lab—an influential external validation likely to accelerate adoption and generate more head-to-head comparisons during the year.
Commercial and Clinical Investment to Support Launch
Targeted hiring in clinical and technical sales plus medical and clinical affairs to accelerate center engagement and enrollment; management plans additional hires as authorization approaches to support commercialization ramp.
Funding and Strategic Investor Support
Completed a $26 million registered direct offering; Bio-Rad participated and retains pro rata ownership just under 10%; proceeds intended to fund simultaneous commercialization (kidney) and R&D expansion into heart transplant testing.
Clear Reimbursement Path in the U.S. and Medicare Rate
Medicare reimbursement for GraftAssure cited at $27.53; company submitted for a MolDx Z-code for the regulated kitted test and is performing a bridging study to align kitted reimbursement with the current lab test, supporting in-house adoption by centers within MolDx jurisdictions.
Organ-Agnostic Platform and Heart Expansion Plan
GraftAssure designed to be organ-agnostic. Company pursuing heart transplant indication: engaging 4–5 heart centers for a ~150-patient study (for CMS) and planning a 510(k) FDA submission with a 90-day review window using the AlloMap predicate—expected execution within the year if samples collected in ~4 months.
Large Market Opportunity and Revenue Model
Management estimates a total addressable market >$2 billion annually. Near-term commercial model: management expects to average ~$1 million in annual revenue per engaged center and notes maintenance spending (~$5.5M/quarter) is covered at about $35M/year revenue assuming software-like gross margins.
IMDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IMDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 26, 2026 | $4.11 | $3.56 | -13.38% |
Nov 10, 2025 | $6.80 | $7.53 | +10.66% |
Aug 11, 2025 | $2.61 | $2.51 | -3.83% |
May 12, 2025 | $2.81 | $2.77 | -1.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Insight Molecular Diagnostics (IMDX) report earnings?
Insight Molecular Diagnostics (IMDX) is schdueled to report earning on May 18, 2026, After Close (Confirmed).
What is Insight Molecular Diagnostics (IMDX) earnings time?
Insight Molecular Diagnostics (IMDX) earnings time is at May 18, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IMDX EPS forecast?
Currently, no data Available